r/Canadapennystocks

$FPC Horne 5: What Comes Next?
▲ 10 r/Canadapennystocks+7 crossposts

$FPC Horne 5: What Comes Next?

Useful $FPC interview covering Horne 5 economics, permitting progress, and next steps.

Would you watch the permit, funding plan, or partner potential first?

Disclaimer: Not financial advice. Do your own DD.

youtube.com
u/Fluffy-Lead6201 — 8 days ago
▲ 5 r/Canadapennystocks+4 crossposts

RTX Revenue Breakdown 2025 – China 6%, Low Concentration Risk

RTX 2025 geographic revenue:

- China: 6% (largest)
- Germany: 4%
- UK: 3%
- Japan: 3%
- Canada: 2%
- Other: 6%

Concentration risk rated low.

Full data: metricshour.com/stocks/rtx

How exposed do you see major defense names to single countries?

u/metricshour — 10 days ago
▲ 6 r/Canadapennystocks+1 crossposts

HydroGraph Clean Power Inc. (CSE: HG): Patented Graphene Production for the Next Generation of Advanced Materials

HydroGraph Clean Power Inc. is a Canadian advanced materials company producing high-purity synthetic fractal graphene for industrial and commercial applications.

Instead of relying on mined graphite, HydroGraph uses a patented blast synthesis process to convert carbon from hydrocarbon gases into graphene inside its Hyperion reactors. The company has reported 99.8% carbon purity for its FGA-1 graphene.

HydroGraph’s Hyperion reactors are small modular production units with a footprint of less than 3 metres by 3 metres. Rather than relying on one large centralized facility, HydroGraph can add more reactors as customer demand grows, allowing production capacity to increase while maintaining consistency from batch to batch.

Graphene and Fractal Graphene

Graphene is a carbon-based advanced material made from carbon atoms connected by strong sp² bonds. This structure helps give graphene its strength, conductivity, barrier properties, and the ability to improve other materials even when added in small amounts.

Traditional graphene is often described as a flat, sheet-like material. HydroGraph produces synthetic fractal graphene with a turbostratic structure, meaning the graphene layers are randomly stacked rather than perfectly aligned. This more complex, interconnected structure gives it higher surface area and more contact points with the materials it is added to. This can help improve dispersion, reinforcement, conductivity, corrosion resistance, and barrier performance across industrial and commercial applications.

HydroGraph is targeting markets where adding small amounts of graphene can improve material performance, including:

  • Thermoplastics
  • Composites and resins
  • Coatings
  • Lubricants
  • Concrete and cement
  • Energy storage
  • Biosensors
  • Elastomers
  • Printed electronics

U.S. Expansion and Production Growth

On April 14th, 2026, HydroGraph announced the opening of its new headquarters in Austin, Texas. The facility expands HydroGraph’s R&D and production capabilities and will support future graphene production in Texas.

Earlier in January 2026, HydroGraph announced construction of two additional Hyperion reactors. Each reactor is expected to have annual production capacity of approximately 10 tons of FGA-1 ultra-pure fractal graphene. The reactors were planned for initial commissioning in Manhattan, Kansas before being relocated to HydroGraph’s U.S. facilities in Austin, Texas.

HydroGraph has also signed a letter of intent with an industrial gas supplier to secure long-term access to high-purity acetylene. Acetylene is a key feedstock in HydroGraph’s blast synthesis process and would support the company’s planned graphene production facility in Texas. The planned facility is expected to include 15 next-generation Hyperion reactors and have annual production capacity of over 350 metric tons of graphene.

Commercial and Technical Partnerships

HydroGraph is building partnerships that support customer testing, application development, and commercial adoption of its fractal graphene in polymers, coatings, and specialty compounds.

  • Graphene Engineering Innovation Centre: In January 2026, HydroGraph expanded its collaboration with the Graphene Engineering Innovation Centre at the University of Manchester by becoming a Tier 1 member. The membership gives HydroGraph access to technical support, testing infrastructure, and a network of industry partners as it develops commercial applications for its fractal graphene.
  • Hubron International: On February 10th, 2026, HydroGraph added Hubron International to its Fractal Graphene Compounding Partner Program. Hubron is a UK-based specialist in polymer compounds and additive masterbatches, giving HydroGraph a partner focused on thermoplastics and polymer applications. Through Hubron’s compounding experience and distributor network, HydroGraph is targeting markets including automotive, construction, electronics, film, pipe, wire and cable, and technical compounding.
  • Broadway Colours: On March 17th, 2026, HydroGraph announced that Broadway Colours Ltd. earned certification as a qualified HydroGraph Compounding Partner. Broadway is a UK manufacturer of masterbatches, compounds, and rotational moulding powders, operating from a 90,000-square-foot facility and supporting plastic manufacturers across the UK and Europe.
  • Sparc Technologies: On March 24th, 2026, HydroGraph announced a Letter of Intent with Sparc Technologies to evaluate HydroGraph’s Fractal Graphene in Sparc’s ecosparc® additives for protective coatings. The collaboration is focused on corrosion protection for steel infrastructure, including energy, marine, mining, transportation, government, and defence markets. Initial testing using HydroGraph’s FGA-1 Fractal Graphene in commercial water-based coating systems showed a 39% to 60% reduction in corrosion spread under ASTM D1654-08 testing.
  • Modern Dispersions Inc: On June 16th, 2026, HydroGraph announced that Modern Dispersions Inc. earned certification as a qualified HydroGraph Compounding Partner. MDI is a U.S.-based specialist in thermoplastic compounds and masterbatch applications, adding another North American partner focused on polymer processing and graphene masterbatch production.

Regulatory Approvals and Commercial Development

  • On February 24th, 2026, HydroGraph announced regulatory approvals covering commercial-scale graphene sales activity in the United States, the United Kingdom, and the European Union.
  • The company received a U.S. EPA TSCA Section 5(e) Order covering two graphene materials. The order authorizes manufacture, processing, distribution, use, and disposal in the United States under specified conditions.
  • HydroGraph also received UK REACH and EU REACH registrations for graphene, allowing commercial manufacture and supply in Great Britain and the European Union.

HydroGraph now has patented graphene production technology, regulatory clearance across the U.S., U.K., and EU, and a modular production system designed to scale with customer demand.

These approvals remove a major regulatory barrier as HydroGraph expands its U.S. production footprint and advances its fractal graphene from customer testing toward commercial use across multiple industrial markets.

Join the Canadian Hidden Gems Discord community: https://discord.gg/ByfkKfHrv

u/Cabininthewoodsdude — 10 days ago
▲ 19 r/Canadapennystocks+5 crossposts

Q2 Earnings call summary HITI Long term position

https://preview.redd.it/ysud29ansm8h1.png?width=960&format=png&auto=webp&s=8eefcb2084ed738408c59b8c6e2577a4cf10f289

SUMMARY :

Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.

Gms on medical cannabis 27%

https://preview.redd.it/dxfwoyrrsm8h1.png?width=1080&format=png&auto=webp&s=998494d53c8a928657380ae87df27dadd8417578

https://preview.redd.it/5chsk63cvm8h1.png?width=3703&format=png&auto=webp&s=3265490f0f01b01e78c58aff9a7cdf47254cf520

Key Strengths of High Tide's Q2 FY2026

1. Strong Revenue Growth

  • Record revenue of CAD $179.3 million.
  • Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.

2. Accelerating EBITDA Growth

  • Record Adjusted EBITDA of CAD $13.9 million.
  • EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.

3. Positive Net Income

  • The company reported positive net income and positive earnings per share (EPS).
  • In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
  • Management expects sustainable NET INCOME

4. Positive Free Cash Flow

  • High Tide generated positive free cash flow and strong operating cash flow.
  • This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.

5. Germany Continues to Exceed Expectations

  • German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
  • Gross margin improved to 27%.
  • Management stated that several internal targets were achieved roughly 90 days ahead of schedule.

6. Rapid Expansion of the Customer Base

  • The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
  • ELITE memberships exceeded 178,000, up 84% year over year.
  • This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
  • The stated goal is to exceed 1 million elite members in the long term.

7. Significant Banking Support

  • The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
  • Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
  • This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.

8. Market Leadership

  • High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
  • The company is also steadily gaining market share in the German medical cannabis market.
  • Raj is targeting 20% ​​market share in Germany and I personally believe 30% is achievable in the long term for several reasons.

Most Bullish Takeaways

If I had to identify nine most bullish developments from the quarter, they would be:

  1. 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
  2. Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
  3. The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
  4. SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
  5. Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
  6. The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
  7. GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
  8. Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
  9. He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.

Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.

HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.

Still think HITI is vastly undiscovered.

Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.

Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.

This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.

The UK is the European market that excites him the most.

The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.

I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.

https://preview.redd.it/v4vyzimjum8h1.png?width=1080&format=png&auto=webp&s=6ad61176cbd950377e2ae4382f61a339e35111ac

Every analyst covering the company has a Buy rating

Canaccord Genuity → Buy, Target $US 5.50

Haywood → Buy, Target $US 5.90

Roth → Buy, target $US 5.00

TD Cowen → Buy, target $6.5 CAD

ATB CAPITAL Target 7$CAD

https://preview.redd.it/xpd8fh61tm8h1.png?width=1080&format=png&auto=webp&s=a079c0bc0e954365e673a9fc457971db0bf68224

company presentation

https://hightideinc.com/presentation/

Long term

reddit.com
u/WilliamBlack97AI — 12 days ago